AMLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMLX is a good buy for a beginner long-term investor with $50,000-$100,000 available. The stock has clear upside catalysts from the Phase III LUCIDITY readout next quarter and an NDA build toward a 2027 launch, while analysts remain broadly bullish and have been raising targets. Despite weak current profitability and mixed technicals, the combination of strong catalyst visibility, adequate cash runway into 2028, and favorable Wall Street sentiment makes AMLX a constructive long-term buy right now.
Technically, AMLX is in a weak-to-neutral setup but near a potentially tradable support zone. Price is 15.5 versus pivot 16.263, with support at 15.044 and then 14.292. MACD histogram is negative and expanding, showing near-term downside momentum, while RSI_6 at 25.378 suggests the stock is oversold. Moving averages are converging, which often signals an inflection point rather than a strong established trend. Overall, the chart is not strongly bullish today, but it is sitting close to support with oversold conditions.
["Last participant in Phase III LUCIDITY trial was dosed, with top-line data expected next quarter.", "Preparing NDA for avexitide, targeting a 2027 launch.", "Plans to launch a disease state education campaign for PBH this summer to build awareness.", "Cash and marketable securities of $279.8 million should fund operations into 2028.", "Analyst sentiment has been improving with multiple target raises and Buy/Outperform ratings."]
["Latest quarter shows no revenue and ongoing net losses.", "EPS remains negative, reflecting continued cash burn.", "Technical momentum is weak with a negative, expanding MACD histogram.", "Insiders have been selling heavily, with selling up sharply over the last month.", "No recent congress trading data and hedge fund activity is neutral, so no extra institutional support signal."]
In Q1 2026, AMLX reported no revenue, so top-line growth is still not established. Net income was -$41.284 million, which improved 14.97% year over year, but EPS was still -0.37 and worsened 11.90% year over year. This is a pre-commercial biotech profile: earnings remain negative, but the balance sheet is strong enough to support development through 2028. The latest quarter season is Q1 2026.
Wall Street sentiment is clearly positive. Recent months show a steady stream of price target increases: Mizuho to $21, Guggenheim to $30, H.C. Wainwright to $34, Stifel initiated Buy at $21, BofA to $19, and Mizuho earlier to $19. The pros view is that avexitide and the Phase 3 LUCIDITY program could unlock a major orphan-drug opportunity with favorable risk/reward. The cons view is that the stock is still dependent on trial success and commercialization remains ahead, so current fundamentals do not yet justify a premium on earnings. Overall, the analyst backdrop is bullish and supportive.
